Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
KRAS G12D Inhibitor
KRAS G12D inhibitor 6 is a selective inhibitor targeting the KRAS G12D mutant, a significant oncogenic driver in various cancers. This compound demonstrates strong inhibitory activity that can facilitate the study of KRAS-mediated signaling pathways and tumor progression. It serves as a valuable tool in cancer research, particularly in developing targeted therapies against KRAS-driven malignancies. -
KRAS Inhibitor
KRAS Inhibitor-37 targets the KRAS protein, exhibiting high affinity with KDs of 0.004 nM, 0.041 nM, 0.019 nM, and 0.144 nM for KRAS wild type, G12D, G12C, and G12V variants, respectively, as determined by SPR binding assays. This compound demonstrates significant anti-proliferative activity, with IC50 values ranging from <2 nM to 14 nM across various cancer cell lines, including H358, SW620, and PANC08.13. KRAS Inhibitor-37 is a valuable tool for advancing research in cancer biology, particularly in studies focused on KRAS-driven malignancies. -
KRAS Inhibitor
KRAS Inhibitor-35 (compound 72) is a potent inhibitor of KRAS with an IC50 of 2 nM. It effectively disrupts KRAS signaling pathways, making it a valuable tool for studying tumor biology and the role of KRAS mutations in cancer research. This compound is suitable for various in vitro and in vivo applications aimed at exploring therapeutic strategies targeting KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS inhibitor-18 is a selective inhibitor targeting the KRAS G12C mutation, demonstrating a potent inhibitory effect with an IC50 of 4.74 µM. This compound effectively inhibits phosphorylated ERK in MIA PaCA-2 and A549 cell lines, with IC50 values of 66.4 µM and 11.1 µM, respectively. KRAS inhibitor-18 is valuable for research applications in pancreatic, colorectal, and lung cancer studies, facilitating investigations into KRAS-driven tumorigenesis and potential therapeutic interventions. -
GTPase Inhibitor
RTIL 13 is a selective inhibitor of dynamin GTPase, demonstrating an IC50 value of 2.3 μM for dynamin I. Additionally, it interacts with the pleckstrin homology lipid-binding domain. RTIL 13 effectively inhibits receptor-mediated endocytosis and synaptic vesicle endocytosis, with IC50 values of 9.3 μM and 7.1 μM, respectively. This compound is valuable for research focused on vesicle trafficking and cellular uptake mechanisms. -
KRASG12D Mutants Inhibitor
KRAS-IN-42 is a covalent inhibitor specifically targeting KRASG12D mutants. This compound exhibits potent activity against KRASG12D-driven cancers, including non-small cell lung cancer and colorectal cancer. It is a valuable tool for researchers studying the molecular mechanisms and therapeutic options for KRASG12D-mutant oncogenesis. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 43 is a selective inhibitor targeting the KRAS G12C mutation, a key driver in various cancers. It demonstrates significant anti-migration and anti-proliferative activities, with IC50 values ranging from 0.001 to 1 µM in H358, A549, and HCC cell lines. This compound holds potential for research applications focused on cancer progression and therapeutic development against KRAS-driven malignancies. -
KRAS Inhibitor
KRAS-IN-41 is a potent inhibitor of the KRAS oncogene, exhibiting IC50 values of less than 0.01 μM against both KRAS G12D and KRAS G12V variants. This compound effectively inhibits the proliferation of RAS mutant cell lines, including GP2D and SW620, demonstrating its potential for therapeutic application. KRAS-IN-41 is suitable for use in cancer research, particularly in studies focused on targeting KRAS mutations. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 50 is a potent small molecule that selectively targets the KRAS G12C mutant protein, exhibiting an IC50 of 46.7 nM. This compound is instrumental in cancer research, particularly in studies focused on KRAS-driven tumors. Its ability to inhibit KRAS G12C activity makes it a valuable tool for investigating therapeutic strategies and potential treatments for malignancies associated with this mutation. -
KRAS Inhibitor
KRAS-IN-47 is a potent inhibitor of the KRAS protein, specifically targeting the KRAS G12V mutant with an IC50 of less than 50 nM. This compound is valuable for research applications focused on understanding KRAS-driven cancers, providing insights into tumor biology and therapeutic resistance mechanisms. The inhibitor's efficacy in modulating KRAS activity makes it a critical tool for studying the role of this oncogene in cancer progression and treatment response. -
KRAS G12D Inhibitor
KRAS G12D inhibitor 28 selectively targets the KRAS G12D mutation, a common oncogenic driver in various cancers. This compound exhibits potent inhibitory activity, making it a valuable tool for studying KRAS-driven tumor biology and developing targeted therapies. Its application in cancer research aids in understanding the molecular mechanisms of KRAS mutations and their role in tumor progression. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 55 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound effectively disrupts KRAS signaling pathways, leading to inhibited cell proliferation in cancer models. It is primarily utilized in research focused on the development of targeted therapies for tumors harboring KRAS G12C mutations. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 51 is a selective inhibitor targeting the mutant form of the KRAS protein, specifically the G12C variant. This compound exhibits significant biological activity in suppressing KRAS-driven signaling pathways, making it a valuable tool for cancer research, particularly in studies focused on tumors harboring KRAS G12C mutations. Its application extends to investigating therapeutic strategies and screening for potential drug candidates in KRAS-related malignancies. -
KRASG12C Inhibitor
SML-8-73-1 is a nucleotide-based inhibitor targeting KRASG12C. This compound demonstrates significant efficacy in inhibiting the activity of KRASG12C, making it a valuable tool for research into non-small cell lung cancer (NSCLC). Its selective inhibition allows for the exploration of KRAS-related signaling pathways and contributes to the understanding of cancer progression and potential therapeutic interventions. -
Rho Signaling Inhibitor
(S)-CCG-1423 is a selective inhibitor of Rho signaling, effectively blocking the nuclear import of myocardin-related transcription factor A (MRTF-A). This compound reduces the nuclear accumulation of MRTF-A, leading to improved glucose uptake and enhanced glucose tolerance in insulin-resistant mouse models. (S)-CCG-1423 demonstrates superior inhibitory activity compared to its SR- and R-isomers, making it a valuable tool for research in the fields of cancer and diabetes. -
KRAS G12C inhibitor
KRAS G12C inhibitor 22 selectively targets the mutant form of the KRAS protein, specifically the G12C variant. This compound demonstrates potent inhibition of KRAS G12C activity, making it a valuable tool for studying its role in cancer signaling pathways. It is primarily utilized in research focused on developing targeted therapies for KRAS-driven malignancies. -
KRAS G12D Inhibitor
INCB159020 is an orally active inhibitor targeting the KRAS G12D mutation, exhibiting a SPR value of 2.2 nM. It demonstrates significant antitumor activity, making it a valuable compound for research focused on cancers driven by KRAS G12D alterations. This reagent is primarily utilized in studies aimed at understanding the mechanisms of KRAS-related oncogenesis and evaluating potential therapeutic strategies. -
Pan RAS Inhibitor
Pan-RAS-IN-7 is a pan RAS inhibitor that targets the RAS signaling pathway, crucial in cancer biology. This compound exhibits significant anti-tumor activity and is valuable for cancer research applications, particularly in the development of antibody-drug conjugates (ADCs). Its ability to inhibit various RAS isoforms makes it a versatile tool for studying RAS-mediated oncogenic processes. -
KARS Inhibitor
KARS-IN-1 is a potent inhibitor of lysyl-tRNA synthetase (KARS), specifically dependent on AKR1C3, with an AC50 of 9.1 nM for human KARS. This compound exhibits anti-proliferative effects in H460 cells, featuring high AKR1C3 expression, and in Hara cells, which have low AKR1C3 expression, with AC50 values of 21 nM and 16 nM, respectively. KARS-IN-1 is valuable for research focused on non-small cell lung cancer (NSCLC) and the therapeutic targeting of KARS in cancer biology. -
KRAS Inhibitor
pan-KRAS-IN-4 is a highly potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for KRAS G12C and 0.19 nM for KRAS G12V. Its specific mechanistic action targets mutated KRAS proteins, making it a valuable tool for studying oncogenic signaling pathways. This compound is particularly relevant for research applications focused on cancer biology, therapeutic development, and the exploration of KRAS-related malignancies. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 34 is a selective inhibitor targeting the KRAS G12C mutation, a common driver in various cancers. This compound demonstrates significant anticancer activity by disrupting KRAS signaling pathways, leading to reduced cell proliferation. It is suitable for research applications focusing on cancer biology, particularly in the development and evaluation of targeted therapies for KRAS-driven tumors. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 68 is a selective inhibitor targeting the KRAS G12C mutation, with an IC50 of 7 nM. It exhibits significant anti-tumor activity, making it a valuable tool for cancer research, particularly in studies focused on KRAS-driven malignancies. This compound is suitable for investigating the efficacy of KRAS-targeted therapies and understanding the underlying mechanisms of KRAS-related tumorigenesis. -
KRasG12C Inhibitor
CFL-120 is a potent inhibitor of the KRasG12C protein. It exhibits significant antiproliferative effects and demonstrates anticancer activity, making it a valuable tool for cancer research. CFL-120 is particularly relevant for studies focused on lung cancer therapeutics. -
KRAS G12D Inhibitor
KRAS G12D Inhibitor 7 is a selective small molecule targeting the KRAS G12D mutation, which is commonly associated with various cancers. This compound demonstrates potent inhibitory activity against KRAS G12D-driven signaling pathways, making it a valuable tool for cancer research, particularly in studies focused on targeted therapies and drug resistance mechanisms. Its specificity for KRAS G12D highlights its potential in elucidating the role of this mutation in tumorigenesis and therapeutic response. -
KRAS G12D Inhibitor
KRAS G12D inhibitor 16 is a selective inhibitor targeting the KRAS G12D mutation, demonstrating potent inhibitory activity with IC50 values of 0.7 nM against KRAS G12D and 0.35 μM against other KRAS G12D variants. This compound is valuable for research into various malignant tumors, including pancreatic ductal adenocarcinoma (PDAC), colon and rectal carcinomas (CRC), and non-small cell lung carcinoma (NSCLC). Its efficacy positions it as a significant tool for investigating KRAS-driven oncogenic pathways and therapeutic strategies. -
KRAS Inhibitor
SOF-436 is a selective KRAS inhibitor that targets SOS1-mediated nucleotide exchange, exhibiting an IC50 of 60 μM. Additionally, it effectively disrupts the interaction between KRAS and the effector protein RAF. This compound is primarily utilized in cancer research, providing insights into KRAS-driven oncogenic pathways. -
Ra Inhibitor
KRAS inhibitor-36 is a selective inhibitor targeting the KRAS Q61H mutant protein. This compound effectively interferes with KRAS signaling pathways, leading to reduced cellular proliferation and survival in KRAS-dependent cancer models. It is primarily utilized in research aimed at elucidating KRAS-related oncogenic mechanisms and developing novel therapeutic strategies for KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 54 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound demonstrates potent inhibition of KRAS G12C-mediated signaling pathways, leading to reduced cellular proliferation in KRAS G12C-driven tumor models. It is primarily used in cancer research, particularly for studying therapeutic strategies against KRAS G12C mutations in various malignancies. -
KRAS Inhibitor
(S,R,S)-BBO-11818 is a selective inhibitor of KRAS, a key oncogenic driver in various cancers. This compound is instrumental in elucidating the role of KRAS in tumorigenesis and has potential applications in developing targeted therapies for KRAS-driven malignancies. It serves as a valuable tool for researchers investigating KRAS signaling pathways and their implications in cancer biology. -
RAS Inhibitor
pan-KRAS-IN-16 is a potent RAS inhibitor that disrupts protein-protein interactions involving RAS effector proteins. This small molecule, derived from an intracellular antibody fragment, binds to a hydrophobic pocket adjacent to the effector-binding switch regions of RAS. By inhibiting these interactions, pan-KRAS-IN-16 effectively blocks endogenous RAS-dependent signaling in tumor cell lines, making it a valuable tool for research in cancer biology and therapeutic development targeting RAS mutation-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 31 is a selective inhibitor targeting the KRAS G12C mutation, which plays a critical role in cancer pathogenesis. This compound demonstrates potent inhibitory activity, making it a valuable tool for research into KRAS-driven malignancies. It is suitable for studies focused on cancer therapeutics and mechanisms of KRAS-associated signaling pathways. -
KRAS Inhibitor
KRAS inhibitor-38 is a selective inhibitor targeting KRAS mutations, specifically KRAS G12C, KRAS G12D, and KRAS G12V. This compound effectively suppresses the activity of these mutant KRAS proteins in vivo, making it a valuable tool for research on KRAS-driven cancers. It is applicable in studies investigating the role of KRAS in tumorigenesis and potential therapeutic strategies for targeting KRAS mutations. -
G12C KRAS Inhibitor
KRAS G12C-IN-71 is a covalent inhibitor targeting the G12C mutation of the KRAS protein, exhibiting a Ki of 380 nM. This compound demonstrates significant biological activity by selectively inhibiting mutant KRAS, making it a valuable tool for research in non-small cell lung cancer. Its application aids in understanding the role of KRAS mutations in cancer progression and therapeutic strategies. -
KRAS G12C Mutant Inhibitor
KRAS G12C-IN-70 is a selective inhibitor that targets the KRAS G12C mutant, effectively disrupting downstream signaling pathways such as RAF-MEK-ERK. This inhibition leads to a reduction in tumor cell proliferation, making KRAS G12C-IN-70 a valuable tool for research into tumors associated with the KRAS G12C mutation, including non-small cell lung cancer and colorectal cancer. Researchers investigating the therapeutic potential of targeting KRAS G12C will find this compound particularly useful. -
KRas Inhibitor
SS-3091 is a pan KRas inhibitor that targets the interaction interfaces of KRas, leading to the destabilization of the ARaf/KRas complex and modulation of downstream signaling pathways. This compound exhibits significant anticancer and antiproliferative effects against various KRas mutant forms, including G12D, G12C, G12V, and G12S, in a range of cancer cell lines. SS-3091 is valuable for research into KRas-mediated signaling and its implications in cancer biology. -
FTase Inhibitor
BIM-46068 is a selective inhibitor of human brain Farnesyltransferase (FTase) with an IC50 of 91.4 nM. This compound effectively inhibits Ras processing in MiaPaCa-2 cancer cells, making it a valuable tool for research on pancreatic cancer. Its ability to specifically target FTase positions BIM-46068 as an important reagent for exploring the molecular mechanisms underlying Ras signaling in cancer. -
KRAS G12C Inhibitor
KRAS Inhibitor-17 is a selective inhibitor targeting the KRAS G12C oncogenic mutation, exhibiting an IC50 of 3.37 µM. It effectively inhibits phosphorylated ERK (p-ERK) with IC50 values of 9.25 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. This compound holds promise for advancing research in pancreatic, colorectal, and lung cancers, contributing to the understanding of KRAS-driven tumorigenesis. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 45 is a selective inhibitor that targets the KRAS G12C mutation, which plays a crucial role in various cancers. This compound demonstrates significant biological activity by inhibiting the downstream signaling pathways associated with KRAS G12C, thereby inducing apoptosis in tumor cells harboring this mutation. It is a valuable tool for cancer research, particularly in studies focusing on personalized medicine and targeted therapies for KRAS G12C-positive tumors. -
KRAS Inhibitor
KRAS inhibitor-21 is a potent inhibitor targeting the KRAS G12C mutation with an IC50 value of less than 0.01 μM. This compound demonstrates significant biological activity in attenuating KRAS-mediated signaling pathways, making it a valuable tool for investigating mechanisms of oncogenic transformation. It is particularly useful in cancer research aimed at exploring therapeutic strategies for KRAS-driven malignancies. -
KRAS Inhibitor
KRAS inhibitor-34 is a selective inhibitor targeting the KRAS protein, exhibiting an IC50 of 6.4 nM. This compound is utilized in tumor research to investigate KRAS-mediated signaling pathways and its role in cancer progression. It provides a valuable tool for studying the therapeutic potential of KRAS inhibition in various malignancies. -
Farnesyl Transferase Inhibitor
(Rac)-Tipifarnib is a potent farnesyl protein transferase inhibitor that disrupts the post-translational modification of Ras proteins. By inhibiting farnesylation, it effectively interferes with the activation and function of Ras, leading to significant antitumor effects. This compound is utilized in research focused on cancer therapeutics and the molecular mechanisms underlying Ras-mediated signaling pathways. -
PAT Inhibitor
PAT-IN-2 is a selective inhibitor of protein acyl transferases (PAT), primarily targeting Erf2 autopalmitoylation. By competitively inhibiting this process, PAT-IN-2 serves as a valuable tool for investigating the role of PAT in cellular signaling and lipid metabolism. Its application in research may provide insights into the regulation of protein function via acylation and the development of therapeutic strategies targeting related pathways. -
KRASG12C Inhibitor
KRASG12C IN-18 is a potent covalent inhibitor targeting the KRASG12C mutation. It effectively engages KRASG12C in both GDP- and GMPPNP-bound states, demonstrating significant antiproliferative activity against KRASG12C and its resistance variants, including KRASG12C/R68S, with low nanomolar IC50 values. This compound exhibits substantial in vivo efficacy in models of KRASG12C-driven solid tumors and KRASG12C/R68S xenografts, making it a valuable tool for research in colorectal cancer. -
RAS Inhibitor
RAS-IN-4 is a RAS inhibitor that exhibits significant antitumor activity. This compound interferes with RAS signaling pathways, making it an important tool for researchers studying cancer biology and therapeutic resistance. RAS-IN-4 can be utilized in various in vitro and in vivo studies aimed at understanding the role of RAS in tumor progression and exploring targeted cancer therapies. -
PAT Inhibitor
PAT-IN-1 is a selective inhibitor of protein acyl transferases (PAT), specifically targeting Erf2 autopalmitoylation. It acts through competitive inhibition, thereby altering lipid modifications that influence protein functionality. This compound is valuable for research applications exploring the role of palmitoylation in cellular signaling and protein interactions. -
Cdc42-ITSN Inhibitor
ZCL279 is a small molecule modulator that selectively inhibits the interaction between Cdc42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 stimulates Cdc42 activation, while at higher concentrations, it exerts a significant inhibitory effect on Cdc42 activity. This dual functionality makes ZCL279 a valuable tool for studying the role of Cdc42 in cellular signaling pathways and its implications in various biological processes and diseases. -
KRAS G12C Inhibitor
ZG1077 is a covalent inhibitor targeting the KRAS G12C mutation. It demonstrates potent inhibitory activity against KRAS-driven cancer cell proliferation, making it a valuable tool for studying non-small cell lung cancer (NSCLC) and other KRAS-related malignancies. This compound facilitates research into therapeutic strategies aimed at inhibiting the KRAS signaling pathway. -
K-Ras PM Localization Inhibitor
Oligomycin D, an antibiotic derived from the strain S. rutgersensis, functions as a potent inhibitor of K-Ras plasma membrane localization. By disrupting K-Ras localization, Oligomycin D plays a critical role in cancer research, offering insights into tumorigenesis and potential therapeutic strategies. Its use in various cancer studies provides valuable data for understanding K-Ras-driven malignancies. -
RAS Inhibitor
RAS-IN-5 is a potent RAS inhibitor that effectively disrupts the interaction between RAF1 and active KRAS mutant or wild-type HRAS proteins. This compound demonstrates significant inhibition of cell viability in KRAS, NRAS, and EGFR mutant cell lines. RAS-IN-5 is valuable for research applications focused on colorectal cancer, liver cancer, and non-small cell lung cancer, providing a critical tool for understanding RAS signaling and its role in tumorigenesis. -
KRAS Inhibitor
KRAS inhibitor-11 is a potent inhibitor targeting the KRAS protein, which plays a critical role in cell signaling pathways associated with cancer proliferation. This compound exhibits significant anti-proliferative effects in KRAS-driven tumors, making it a valuable tool for cancer research. It is suitable for studies focusing on KRAS mutations and their implications in oncogenic signaling and therapeutic resistance.
